NLRC5, a promising new entry in tumor immunology

The urgent need to recover MHC class I in cancers for effective immunotherapy

(2016) Federico Garrido et al.   CURRENT OPINION IN IMMUNOLOGY

T Cell Priming by ActivatedNlrc5-Deficient Dendritic Cells Is Unaffected despite Partially Reduced MHC Class I Levels

(2016) Giorgia Rota et al.   JOURNAL OF IMMUNOLOGY

Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

NLRC5/MHC class I transactivator is a target for immune evasion in cancer

(2016) Sayuri Yoshihama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions

(2016) Kristina Ludigs et al.   Nature Communications

NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8+ T lymphocytes

(2016) Galaxia M. Rodriguez et al.   OncoImmunology

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma

(2015) Masafumi Seki et al.   Nature Communications

NLRC5 Exclusively Transactivates MHC Class I and Related Genes through a Distinctive SXY Module

(2015) Kristina Ludigs et al.   PLoS Genetics

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

(2014) Liufu Deng et al.   IMMUNITY

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Cutaneous melanoma

(2013) Alexander MM Eggermont et al.   LANCET

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Exploiting the Mutanome for Tumor Vaccination

(2012) J. C. Castle et al.   CANCER RESEARCH

NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens

(2012) Yikun Yao et al.   CELL RESEARCH

Regulation of Class I Major Histocompatibility Complex (MHC) by Nucleotide-binding Domain, Leucine-rich Repeat-containing (NLR) Proteins

(2012) Gregory R. Robbins et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

NLRC5 Controls Basal MHC Class I Gene Expression in an MHC Enhanceosome-Dependent Manner

(2012) A. Neerincx et al.   JOURNAL OF IMMUNOLOGY

NLRC5 Deficiency Selectively Impairs MHC Class I- Dependent Lymphocyte Killing by Cytotoxic T Cells

(2012) F. Staehli et al.   JOURNAL OF IMMUNOLOGY

NLRC5 Cooperates with the RFX Transcription Factor Complex To Induce MHC Class I Gene Expression

(2012) T. B. Meissner et al.   JOURNAL OF IMMUNOLOGY

Novel insights into the molecular mechanisms of HLA class I abnormalities

(2011) Barbara Seliger   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Nucleotide-Binding Oligomerization Domain-Like Receptor NLRC5 Is Involved in IFN-Dependent Antiviral Immune Responses

(2010) Sven Kuenzel et al.   JOURNAL OF IMMUNOLOGY

NLR family member NLRC5 is a transcriptional regulator of MHC class I genes

(2010) T. B. Meissner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy

(2008) Rafael Carretero et al.   IMMUNOGENETICS